Cover Image
市場調查報告書

H3N2感染疾病:開發平台分析

H3N2 Infection - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 268982
出版日期 內容資訊 英文 107 Pages
訂單完成後即時交付
價格
Back to Top
H3N2感染疾病:開發平台分析 H3N2 Infection - Pipeline Review, H1 2016
出版日期: 2016年03月09日 內容資訊: 英文 107 Pages
簡介

H3N2感染疾病是由於H3N2變異型流感病毒所引起。常見的症狀有咳嗽,喉嚨疼痛,鼻涕·鼻塞,發冷,噁心,嘔吐,腹瀉等。危險因素有年齡,慢性疾病 (氣喘,糖尿病,心臟病,免疫系低,神經學的疾病/神經發育障礙等) 。治療方法包含抗病毒藥物和抗生素等。

本報告提供H3N2感染疾病的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

H3N2感染疾病概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

開發治療藥的企業

  • AIMM Therapeutics B.V.
  • Aphios Corporation
  • Crucell N.V.
  • CSL Limited
  • Glide Pharmaceutical Technologies Limited
  • ILiAD Biotechnologies, LLC
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Medicago Inc.
  • MedImmune, LLC
  • Mucosis B.V.
  • NanoViricides, Inc.
  • Novavax, Inc.
  • OPKO Health, Inc.
  • Sarepta Therapeutics, Inc.
  • 武田藥品工業
  • Visterra, Inc.
  • Zydus Cadila Healthcare Limited

治療藥的評估

  • 單獨療法的情況
  • 聯合治療的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • APP-0205
  • APP-309
  • Aspidasept
  • C-05
  • CR-8020
  • CR-9114
  • FluGEM
  • Gamma-Flu
  • 流感 病毒株型 A/H3N2 (一價) 疫苗
  • 流感 病毒株型 A/H3N2 疫苗
  • 流感 病毒株型 A/H3N2 疫苗
  • 流感 病毒株型 A/H1N1 + A/H3N2 + A/H5N1 (類病毒顆粒) 疫苗
  • 流感 病毒株型 A/H1N1 + A/H3N2 + A/H5N1 疫苗
  • 流感 病毒株型 A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata (四價, split virion) 疫苗
  • 流感 病毒株型 A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria (四價) 疫苗
  • 流感 病毒株型 A/H1N1 + A/H3N2 + B/Yamagata (三價, split virion) 疫苗
  • 流感 病毒株型 A/H1N1 + A/H3N2 + B/Yamagata (三價, 類病毒顆粒) 疫苗
  • 流感 病毒株型 A/H1N1 + A/H3N2 + B/Yamagata (三價, 類病毒顆粒) 疫苗
  • 流感 病毒株型 A/H1N1 + A/H3N2 + B (四價, 類病毒顆粒) 疫苗
  • 流感 病毒株型 A/H1N1 + A/H3N2 + B (三價, split virion) 疫苗
  • 流感 病毒株型 A/H1N1 + A/H3N2 + B (三價, split virion) 疫苗
  • 流感 病毒株型 A/H1N1 + A/H3N2 + B (三價, split virion) 疫苗
  • JNJ-872
  • NVINF-1
  • NVINF-2
  • 百日咳 病毒株型 BPZE1 疫苗
  • PNSIA-28
  • radavirsen
  • RSV·A型流感感染疾病小分子
  • TXB-248
  • VIS-410

開發中產品的最新趨勢

暫停的計劃

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7717IDB

Summary

Global Markets Direct's, 'H3N2 Infection - Pipeline Review, H1 2016', provides an overview of the H3N2 Infection pipeline landscape.

The report provides comprehensive information on the therapeutics under development for H3N2 Infection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for H3N2 Infection and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of H3N2 Infection
  • The report reviews pipeline therapeutics for H3N2 Infection by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved H3N2 Infection therapeutics and enlists all their major and minor projects
  • The report assesses H3N2 Infection therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for H3N2 Infection

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for H3N2 Infection
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding H3N2 Infection pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • H3N2 Infection Overview
  • Therapeutics Development
    • Pipeline Products for H3N2 Infection - Overview
    • Pipeline Products for H3N2 Infection - Comparative Analysis
  • H3N2 Infection - Therapeutics under Development by Companies
  • H3N2 Infection - Therapeutics under Investigation by Universities/Institutes
  • H3N2 Infection - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • H3N2 Infection - Products under Development by Companies
  • H3N2 Infection - Products under Investigation by Universities/Institutes
  • H3N2 Infection - Companies Involved in Therapeutics Development
    • AIMM Therapeutics B.V.
    • Aphios Corporation
    • Crucell N.V.
    • CSL Limited
    • Glide Pharmaceutical Technologies Limited
    • ILiAD Biotechnologies, LLC
    • Inovio Pharmaceuticals, Inc.
    • Johnson & Johnson
    • Medicago Inc.
    • MedImmune, LLC
    • Mucosis B.V.
    • NanoViricides, Inc.
    • Novavax, Inc.
    • OPKO Health, Inc.
    • Sarepta Therapeutics, Inc.
    • Takeda Pharmaceutical Company Limited
    • Visterra, Inc.
    • Zydus Cadila Healthcare Limited
  • H3N2 Infection - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • APP-0205 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • APP-309 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Aspidasept - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • C-05 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CR-8020 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CR-9114 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FluGEM - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gamma-Flu - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza [strain A/H3N2] (monovalent) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza [strain A/H3N2] vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza [strain A/H3N2] vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (tetravalent, split virion) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent, virus like particle) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JNJ-872 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NVINF-1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NVINF-2 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pertussis [strain BPZE1] vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PNSIA-28 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • radavirsen - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for RSV and Influenza A Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TXB-248 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VIS-410 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • H3N2 Infection - Recent Pipeline Updates
  • H3N2 Infection - Dormant Projects
  • H3N2 Infection - Product Development Milestones
    • Featured News & Press Releases
      • Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further Development Of Influenza Drug AVI-7100
      • Oct 09, 2012: NanoViricides's Oral FluCide Drug Candidate Found To Be Superior To Oseltamivir In Reduction Of Virus Load And Lung Damage Pathology In Animal Models With H3N2 Influenza
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for H3N2 Infection, H1 2016
  • Number of Products under Development for H3N2 Infection - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H1 2016
  • H3N2 Infection - Pipeline by AIMM Therapeutics B.V., H1 2016
  • H3N2 Infection - Pipeline by Aphios Corporation, H1 2016
  • H3N2 Infection - Pipeline by Crucell N.V., H1 2016
  • H3N2 Infection - Pipeline by CSL Limited, H1 2016
  • H3N2 Infection - Pipeline by Glide Pharmaceutical Technologies Limited, H1 2016
  • H3N2 Infection - Pipeline by ILiAD Biotechnologies, LLC, H1 2016
  • H3N2 Infection - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016
  • H3N2 Infection - Pipeline by Johnson & Johnson, H1 2016
  • H3N2 Infection - Pipeline by Medicago Inc., H1 2016
  • H3N2 Infection - Pipeline by MedImmune, LLC, H1 2016
  • H3N2 Infection - Pipeline by Mucosis B.V., H1 2016
  • H3N2 Infection - Pipeline by NanoViricides, Inc., H1 2016
  • H3N2 Infection - Pipeline by Novavax, Inc., H1 2016
  • H3N2 Infection - Pipeline by OPKO Health, Inc., H1 2016
  • H3N2 Infection - Pipeline by Sarepta Therapeutics, Inc., H1 2016
  • H3N2 Infection - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
  • H3N2 Infection - Pipeline by Visterra, Inc., H1 2016
  • H3N2 Infection - Pipeline by Zydus Cadila Healthcare Limited, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • H3N2 Infection Therapeutics - Recent Pipeline Updates, H1 2016
  • H3N2 Infection - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for H3N2 Infection, H1 2016
  • Number of Products under Development for H3N2 Infection - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top